



UNIVERSITÀ
di **VERONA**

Dipartimento
di **SCIENZE GIURIDICHE**

Diletta Danieli

**The EU pharmaceutical market:
crossing paths between regulation,
competition law and free movement**



Edizioni Scientifiche Italiane

DILETTA DANIELI

The EU pharmaceutical market:
crossing paths between regulation,
competition law and free movement



Edizioni Scientifiche Italiane

TABLE OF CONTENTS

INTRODUCTION	1
CHAPTER I – <i>Setting the scene: the market framework for pharmaceuticals</i>	
1. Introduction to the EU market framework for pharmaceuticals: between general and sector-specific rules	5
2. The “actors” in the pharmaceutical market	8
3. The relevant regulatory framework: patents and other intellectual property rights	11
3.1. Market access for pharmaceuticals	15
3.2. Pricing and reimbursement of pharmaceuticals	19
4. An overview of the European Commission’s initiatives regarding competition law in the pharmaceutical sector	22
CHAPTER II – <i>Parallel trade and excessive pricing: competition vis-à-vis pharmaceutical pricing regulation</i>	
1. The context of pharmaceutical parallel trade: free movement rules, exhaustion of intellectual property rights and economic considerations	27
2. EU case law	32
3. Assessing the implications of pharmaceutical parallel trade on the application of EU competition law	42
4. The context of excessive pricing in the pharmaceutical sector: is there room for EU competition law enforcement?	52
5. Member States’ case law	56
6. Assessing the lessons from Italy and the UK: convergences and divergences	63
7. A prospective look at the enforcement against restrictions to parallel trade and excessive pricing in the pharmaceutical sector	69

CHAPTER III – *Agreements in the pharmaceutical sector: competition vis-à-vis patent law (with a dose of regulation)*

- | | |
|---|-----|
| 1. Reverse payment settlement agreements between originator and generic companies: EU case law | 73 |
| 1.1. UK case law | 89 |
| 1.2. US case law | 96 |
| 2. Co-promotion agreements between originator and generic companies: case law | 109 |
| 3. Unravelling the complexity of the “by object box” (part I): the interface with patent law and the convergences between the two sides of the Atlantic | 111 |
| 4. Horizontal agreements between originator companies: case law | 125 |
| 5. Unravelling the complexity of the “by object box” (part II): agreements to disseminate misleading information and the interface with pharmaceutical regulation | 137 |

CHAPTER IV – *Patent-related strategies by dominant pharmaceutical undertakings: competition vis-à-vis patent law vis-à-vis regulation*

- | | |
|--|-----|
| 1. The broad category of abusive practices in the pharmaceutical sector: EU case law | 145 |
| 1.1. Member States’ case law | 155 |
| 1.2. US case law | 162 |
| 2. Assessing the appropriate competition law standards: the importance of innovation-related benchmarks | 170 |
| 3. Reverse payment patent settlement agreements as an abuse of dominant position: first appraisals in the case law | 180 |
| 4. Assessing the “missing link” between patent settlement agreements and product-hopping strategies | 183 |

FINAL REMARKS – *What role for competition law in the EU «Single Market in Pharmaceuticals»?* 189

Bibliography 197

Table of cases 213